Pharmaceutical major Dr Reddy’s Laboratories (DRL) has commissioned the commercial scale manufacturing facility for pharma grade mPEG alcohols at its Cuernavaca facility in Mexico.
mPEG alcohols are the key raw materials for Activated mPEG, extensively used for pegylation with biologic drugs and increasingly for peptides and small molecule pharmaceuticals. Dr Reddy’s has announced ‘PEGtech’ as its product brand for its extensive range of activated mPEGs.
The new assets in Mexico represent a significant investment in a dedicated facility operated to c-GMP standards which is capable of producing a wide range of molecular weight mPEGs and has a multi-tonne annual capacity.
The mPEG alcohol manufactured in Mexico will be supplied to Dr Reddy’s c-GMP facility in Mirfield, UK, where commercial scale activation is carried out.
PEGtech branding has been used to bring together a broad product range comprising a variety of activating groups and molecular weights (5-60 kDa), which are now fully supported by backward integration to the key starting materials. While a part of the total activated mPEG production would be used by DRL for captive purposes, rest would be sold to its customers. However, the company officials refused to share the quantum of production available for sale to customers and the investments made on the facility so far.
“Our investment in the world class mPEG alcohol facility in Mexico underlines our commitment to the growing market for activated mPEGs. By introducing the PEGtech brand our customers can be assured of the same high quality standards and customer service as they develop their PEGylated biologic drugs or small molecules from the laboratory right through to commercial applications,” Satish Reddy, MD and COO, Dr Reddy’s, said.
Comments